Holen Sie sich die Stockscreener-App
5.81
0.87%
0.05
Handel nachbörslich:
5.81
Schlusskurs vom Vortag:
$5.76
Offen:
$5.8
24-Stunden-Volumen:
1.10M
Relative Volume:
0.44
Marktkapitalisierung:
$1.18B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-17.61
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
+3.01%
1M Leistung:
-9.92%
6M Leistung:
+145.15%
1J Leistung:
+91.12%
1-Tages-Spanne:
$5.72
$5.96
1-Wochen-Bereich:
$5.468
$5.96
52-Wochen-Spanne:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.81 | 1.17B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Why Savara Inc. stock is favored by top institutions2025 Stock Rankings & Growth Focused Entry Reports - ulpravda.ru
Savara Highlights Autoimmune PAP Burden in Updated Presentation - TipRanks
How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - ulpravda.ru
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx - simplywall.st
How Savara Inc. stock benefits from global expansionJuly 2025 Movers & Fast Gaining Stock Strategy Reports - ulpravda.ru
Will Savara Inc. stock outperform tech sector in 20252025 Price Momentum & Daily Price Action Insights - ulpravda.ru
How Savara Inc. (YB4P) stock compares with top peersProduct Launch & Technical Confirmation Alerts - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI - PharmiWeb.com
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance
Will Savara Inc. (YB4P) stock rise with strong economyBuy Signal & Fast Exit Strategy with Risk Control - ulpravda.ru
Will Savara Inc. stock reach all time highs in 20252025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru
Aug Volume: How Savara Inc stock compares to growth peersRisk Management & Growth Focused Investment Plans - moha.gov.vn
Will Savara Inc. stock benefit from sector rotation2026 world cup usa national team group stage key players transition play expert forecast insights - ulpravda.ru
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo
Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat
Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo
With 37% Ownership in Savara Inc. (NASDAQ:SVRA), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA - MarketBeat
Gap Down: Is Savara Inc YB4P stock a buy for dividend portfolios2025 Trade Ideas & AI Based Buy and Sell Signals - moha.gov.vn
How Savara Inc. stock reacts to Fed rate cutsSector Performance Review & Your Free Entry to Smart Investing Starts Here - bollywoodhelpline.com
Savara price target raised to $10 from $8 at HC Wainwright - MSN
Savara Inc. ticks higher amid takeover speculation - MSN
Market Review: How MTEN stock performs in high volatility marketsMarket Trend Report & Accurate Intraday Trade Tips - moha.gov.vn
What is HC Wainwright's Forecast for Savara FY2027 Earnings? - MarketBeat
Savara (SVRA) Stock Price, Quote, News & History - Benzinga
FY2029 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission By Investing.com - Investing.com South Africa
Savara (SVRA) Receives Revised Buy Rating from HC Wainwright & C - GuruFocus
Savara stock price target raised to $10 from $8 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission - Investing.com Nigeria
Savara stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com Nigeria
How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st
Savara resubmits BLA for rare lung disease treatment with new manufacturer - Investing.com Nigeria
Savara (SVRA) Resubmits Molbreevi BLA to FDA for Autoimmune PAP Treatment - GuruFocus
Savara Resubmits Molbreevi Application to FDA for Rare Lung Disease - marketscreener.com
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):